Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1316000771
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1515 Holcombe Blvd
Houston, TX, 77030
Phone (713) 792-6161
Groups this clinician bills Medicare through
Medicare paid, 2024
$62K
636 services
Medicare patients, 2024
164
Average age 73
Drug cost, 2024
$2.5M
341 prescriptions
Company payments, 2025
$48K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Courtney D Dinardo was code 99233 (hospital e&m - subsequent), 267 times for 51 patients. In total Courtney D Dinardo billed 636 services in 17 codes, and Medicare paid $62K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-10-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 267 | 51 | $91.99 | $25K |
| 99215 Office E&M - Established | Facility | 219 | 83 | $108.08 | $24K |
| 99214 Office E&M - Established | Facility | 44 | 29 | $69.65 | $3,065 |
| 99223 Hospital E&M - Initial | Facility | 34 | 33 | $133.98 | $4,555 |
| 99205 Office E&M - New | Facility | 22 | 22 | $139.27 | $3,064 |
By year: 2022 $85K for 879 services; 2023 $68K for 681 services; 2024 $62K for 636 services.
Medicare prescription drug claims, 2024
In 2024, the drug Courtney D Dinardo prescribed most often to Medicare patients was Valacyclovir (Valacyclovir Hcl), with 32 prescriptions and refills. In total Courtney D Dinardo wrote 341 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Valacyclovir Valacyclovir Hcl | 32 | 47 | 18 | $714 |
| Inqovi Decitabine/Cedazuridine | 27 | 27 | Under 11 | $227K |
| Tibsovo Ivosidenib | 26 | 26 | Under 11 | $797K |
| Venclexta Venetoclax | 26 | 27 | Under 11 | $49K |
| Idhifa Enasidenib Mesylate | 23 | 23 | Under 11 | $769K |
| Levofloxacin Generic | 23 | 24 | 14 | $208 |
| Scemblix Asciminib Hydrochloride | 12 | 12 | Under 11 | $213K |
Brand drugs: - claims; generic drugs: 198 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Courtney D Dinardo $48K ($48K in general payments such as food, travel and fees) from 16 companies. The largest payer was Abbvie Inc. with $11K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 5 | $11K |
| Rigel Pharmaceuticals, Inc. RIGL | 6 | $9,421 |
| Genmab A/S GMAB | 1 | $7,125 |
| Syndax Pharmaceuticals, Inc. SNDX | 5 | $5,078 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $4,775 |
| Astellas Pharma US Inc 4503.T | 2 | $3,630 |
| Genentech USA, Inc. ROG.SW | 5 | $2,024 |
| BeOne Medicines USA, Inc. ONC | 1 | $1,875 |
| Daiichi Sankyo Inc. 4568.T | 1 | $1,774 |
| Servier Pharmaceuticals LLC | 3 | $728 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.